Relmada Therapeutics is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) diseases. Its lead product candidate, REL-1017, an NMDA receptor antagonist, is in late-stage development as an adjunctive treatment for major depressive disorder.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.